<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Comans-Bitter, W.M.</title>
    <link>http://repub.eur.nl/res/aut/2851/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay (Article)</title>
      <link>http://repub.eur.nl/res/pub/22073/</link>
      <pubDate>2010-09-01T00:00:00Z</pubDate>
      <description>Nowadays, the presence of specific genetic aberrations is progressively used for classification and treatment stratification, because acute leukemias with the same oncogenetic aberration generally form a clinically and diagnostically homogenous disease entity with comparable prognosis. Many oncogenetic aberrations in acute leukemias result in a fusion gene, which is transcribed into fusion transcripts and translated into fusion proteins, which are assumed to play a critical role in the oncogenetic process. Fusion gene aberrations are detected by karyotyping, FISH, or RT-PCR analysis. However, these molecular genetic techniques are laborious and time consuming, which is in contrast to flow cytometric techniques. Therefore we developed a flow cytometric immunobead assay for detection of fusion proteins in lysates of leukemia cell samples by use of a bead-bound catching antibody against one side of the fusion protein and fluorochrome-conjugated detection antibody. So far, we have been able to design such fusion protein immunobead assays for BCR-ABL, PML-RARA, TEL-AML1, E2A-PBX1, MLL-AF4, AML1-ETO and CBFB-MYH11. The immunobead assay for detection of fusion proteins can be performed within 3 to 4 hours in a routine diagnostic setting, without the need of special equipment other than a flow cytometer. The novel immunobead assay will enable fast and easy classification of acute leukemia patients that express fusion proteins. Such patients can be included at an early stage in the right treatment protocols, much faster than by use of current molecular techniques. The immunobead assay can be run in parallel to routine immunophenotyping and is particularly attractive for clinical settings without direct access to molecular diagnostics.</description>
    </item> <item>
      <title>Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/24568/</link>
      <pubDate>2009-04-24T00:00:00Z</pubDate>
      <description>BCR-ABL fusion proteins show increased signaling through their ABL tyrosine kinase domain, which can be blocked by specific inhibitors, thereby providing effective treatment. This makes detection of BCR-ABL aberrations of utmost importance for diagnosis, classification and treatment of leukemia patients. BCR-ABL aberrations are currently detected by karyotyping, fluorescence in situ hybridization (FISH) or PCR techniques, which are time consuming and require specialized facilities. We developed a simple flow cytometric immunobead assay for detection of BCR-ABL fusion proteins in cell lysates, using a bead-bound anti-BCR catching antibody and a fluorochrome-conjugated anti-ABL detection antibody. We noticed protein stability problems in lysates caused by proteases from mature myeloid cells. This problem could largely be solved by adding protease inhibitors in several steps of the immunobead assay. Testing of 145 patient samples showed fully concordant results between the BCR-ABL immunobead assay and reverse transcriptase PCR of fusion gene transcripts. Dilution experiments with BCR-ABL positive cell lines revealed sensitivities of at least 1%. We conclude that the BCR-ABL immunobead assay detects all types of BCR-ABL proteins in leukemic cells with high specificity and sensitivity. The assay does not need specialized laboratory facilities other than a flow cytometer, provides results within ∼4h, and can be run in parallel to routine immunophenotyping.</description>
    </item> <item>
      <title>Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children (Article)</title>
      <link>http://repub.eur.nl/res/pub/9829/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>X-linked agammaglobulinemia (XLA) is characterized by a severe B-cell
      deficiency, resulting from a differentiation arrest in the bone marrow
      (BM). Because XLA is clinically and immunologically heterogeneous, we
      investigated whether the B-cell differentiation arrest in BM of XLA
      patients is heterogeneous as well. First, we analyzed BM samples from 19
      healthy children by flow cytometry. This resulted in a normal B-cell
      differentiation model with eight consecutive stages. Subsequently, we
      analyzed BM samples from nine XLA patients. Eight patients had amino acid
      substitutions in the Bruton's tyrosine kinase (BTK) domain or premature
      stop codons, resulting in the absence of functional BTK proteins. In seven
      of these eight patients a major differentiation arrest was observed at the
      transition between cytoplasmic Ig(mu-) pre-B-I cells and cytoplasmic
      Ig(mu+) pre-B-II cells, consistent with a role for BTK in pre-B-cell
      receptor signaling. However, one patient exhibited a very early arrest at
      the transition between pro-B cells and pre-B-I cells, which could not be
      explained by a different nature of the BTK mutation. We conclude that the
      absence of functional BTK proteins generally leads to an almost complete
      arrest of B-cell development at the pre-B-I to pre-B-II transition. The
      ninth XLA patient had a splice site mutation associated with the presence
      of low levels of wild-type BTK mRNA. His BM showed an almost normal
      composition of the precursor B-cell compartment, suggesting that low
      levels of BTK can rescue the pre-B-cell receptor signaling defect, but do
      not lead to sufficient numbers of mature B lymphocytes in the peripheral
      blood.</description>
    </item> <item>
      <title>Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease? (Article)</title>
      <link>http://repub.eur.nl/res/pub/9285/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Autoimmune lymphoproliferative syndrome (ALPS) is characterized by
          autoimmune features and lymphoproliferations and is generally caused by
          defective Fas-mediated apoptosis. This report describes a child with
          clinical features of ALPS without detectable Fas expression on freshly
          isolated blood leukocytes. Detection of FAS transcripts via real-time
          quantitative PCR made a severe transcriptional defect unlikely. Sequencing
          of the FAS gene revealed a 20-nucleotide duplication in the last exon
          affecting the cytoplasmic signaling domain. The patient was homozygous for
          this mutation, whereas the consanguineous parents and the siblings were
          heterozygous. The patient reported here is a human homologue of the
          Fas-null mouse, inasmuch as she carries an autosomal homozygous mutation
          in the FAS gene and she shows the severe and accelerated ALPS phenotype.
          The heterozygous family members did not have the ALPS phenotype,
          indicating that the disease-causing FAS mutation in this family is
          autosomal recessive.</description>
    </item> <item>
      <title>Longitudinal survey of lymphocyte subpopulations in the first year of life (Article)</title>
      <link>http://repub.eur.nl/res/pub/9310/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Age-matched reference values for lymphocyte subpopulations are generally
          obtained via cross-sectional studies, whereas patients are followed
          longitudinally. We performed a detailed longitudinal analysis of the
          changes in lymphocyte subpopulations in a group of 11 healthy infants
          followed from birth up to 1 y of age, with special attention for early
          developmental markers, markers of maturation, and markers of activation.
          We found that T and B lymphocytes increased at 1 and 6 wk of age,
          respectively. In contrast, NK cells showed a sharp decline directly after
          birth, suggesting that they are more important during pregnancy than
          thereafter. CD45RA+--mainly CD4+--naive T lymphocytes were high at birth,
          and increased further during the first year of life; they form a large
          expanding pool of cells, ready for participation in primary immune
          responses. The absolute counts of CD45RO+ memory T lymphocytes were
          similar in infants and adults, albeit with a lower level of expression of
          CD45RO on infant T lymphocytes. Almost all infant T lymphocytes expressed
          CD38 throughout the first year of life. The abundant expression of CD38 on
          an infant's T lymphocytes might be related to a greater metabolic need of
          the large population of naive untriggered cells that are continually
          involved in primary immune responses during the first year of life. The
          high B lymphocyte counts in infants mainly concerned CD38+ B lymphocytes
          throughout the first year of life. Also, the relative frequencies of CD1c+
          and CD5+ B lymphocytes were higher throughout the first year of life than
          in adults. Therefore, CD1c, CD5, and CD38 could be markers of untriggered
          B lymphocytes. In conclusion, our longitudinal survey of T and B
          lymphocytes, NK cells, and their subpopulations during the first year of
          life helps to complete the picture of lymphocyte development in infants.
          This information contributes to the correct interpretation of data from
          infants with possible immune disorders.</description>
    </item> <item>
      <title>Correction for erythroid cell contamination in microassay for immunophenotyping of neonatal lymphocytes (Article)</title>
      <link>http://repub.eur.nl/res/pub/9083/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>Immunophenotyping of blood lymphocyte subpopulations in neonates and young
          infants is hampered by the limited amount of blood that can be collected.
          Contamination of the flow cytometric "lympho-gate" by normoblasts and
          analysed erythrocytes, and therefore the underestimation of the relative
          frequencies of lymphocyte subpopulations, interferes with the precise
          calculation of absolute counts. A microassay was developed by adapting the
          lysed whole blood technique. Triple immunostaining in a single antibody
          staining step was used to reduce washing steps and cell loss. Introduction
          of a triple staining for CD71 (expressed by erythroid precursors),
          glycophorin A (GpA, expressed by all erythroid cells), and CD45 (expressed
          by all leucocytes) permitted the relative frequencies of normoblasts
          (CD71(+)/GpA+/CD45(-) population) and unlysed erythrocytes
          (CD71(-)/GpA+/CD45(-) population)to be identified and measured within the
          "lympho-gate" of neonatal cord blood samples. Particularly high
          frequencies were found (median: 31%) in cord blood samples from preterm
          neonates. These erythroid cells disappear rapidly by 1 week of age The
          relative frequencies of erythroid cells can be used to calculate correct
          lymphocyte subpopulation values. Using only 0.5-0.8 ml of blood, this
          micro- assay would also be suitable for rapid prenatal immunodiagnosis of
          congenital immunodeficiencies.</description>
    </item>
  </channel>
</rss>